Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
- MHLW Panel to Review Tecentriq’s SCLC Use and More for September OK
July 23, 2019
- Nobelpharma’s Tympanic Membrane Perforation Treatment Up for MHLW Panel Review on Aug. 1
July 23, 2019
- LDP’s Eto Secures Upper House Seat
July 22, 2019
- PMDA Reviewing Risks for Xeljanz and More
July 22, 2019
- Label Revisions Ordered for Opdivo, Keytruda, Ibrance and More
July 10, 2019
- LDP Lawmaker Seiichi Eto Launches Campaign for Upper House Election
July 5, 2019
- No Discussion in Progress for Health Coverage of Risk Reducing Mastectomies for Breast Cancer: Health Minister
July 4, 2019
- Hayashi of Japan Pension Service Tapped for Economic Affairs Division Director: MHLW Personnel Shakeup
July 3, 2019
- Biosimilar Guidelines Nearing 1st Revision in 10 Years, MHLW Taking Public Comments
July 2, 2019
- JPWA Fears October Price Revision Will “Set Back” Efforts to Improve Distribution Practices, Asks Govt for Support
July 1, 2019
- Eylea Gets Orphan Status for Neovascular Glaucoma
July 1, 2019
- MHLW Data Show Big Improvement in Single-Product, Single-Price Transaction Rates
July 1, 2019
- Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”
June 28, 2019
- PMD Amendment Bill Put under Continued Diet Review
June 28, 2019
- Chuikyo Reps Give Kudos to Formulary Initiatives, but Wary on Creating Medical Fees
June 27, 2019
- Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
- MHLW to Conduct Drug Price Survey before October Tax Hike: Chuikyo
June 27, 2019
- No Established Definition Is in Place for Formulary: Govt
June 27, 2019
- Janssen’s HIV Drug Symtuza to Join NHI Price List on July 3
June 27, 2019
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…